HIV-2NIH-z, SIVMAC251, and SIVAGM208K occurs with high titer, suggesting conservation of epitopes and mechanism(s) of neutralization. The V3 regions of HIV-2 and SIV isolates, minimally related to the HIV-1 homolog, share significant sequence homology and are immunogenic in monkeys as well as in humans. Whereas the crown of the V3 loop is cross-reactive among HIV-1 isolates and elicits neutralizing antibodies of broad specificity, the SIV and especially HIV-2 crown peptides were not well recognized by cross-neutralizing antisera. V3 loop peptides of HIV-2 isolates did not elicit neutralizing antibodies in mice, guinea pigs, or a goat and together with SIV V3 peptides did not inhibit serum neutralization of HIV-2 and SIV. Thus, the V3 loops of HIV-2 and SIV do not appear to constitute simple linear neutralizing epitopes. In view of the immunogenicity of V3 peptides, the failure of conserved crown peptides to react with natural sera implies a significant role of loop conformation in antibody recognition. Our studies suggest that in addition to their grouping by envelope genetic relatedness, HIV-2 and SIV are neutralized similarly to each other but differently from HIV-1. The use of linear peptides of HIV-2 and SIV as immunogens may require greater attention to microconformation, and alternate subunit approaches may be needed in exploiting these viruses as vaccine models. Such approaches may also be applicable to the HIV-1 system in which conformational epitopes, in addition to the V3 loop, participate in virus neutralization.
The ability of retroviruses to integrate into the host cell genome and establish persistent infection, together with their ability to disrupt normal gene regulation and function, has produced one of the principal challenges in the development of an AIDS vaccine. Attenuated or inactivated preparations of other viral types have proven to be effective vaccines. However, a safer approach for human immunodeficiency virus type 1 (HIV-1) involves identification and use of viral nucleic acid-free immunogenic subunits capable of eliciting protective humoral and cellular immunity.
Animal models are crucial for testing putative vaccines. Because of the protected status of primates (chimpanzees and gibbons) susceptible to HIV-1 infection, a sufficient number of animals is not always available for necessary studies. The ability of HIV-2 (7, 21, 26) and simian immunodeficiency virus (SIV) (4, 18) to infect macaques provides alternative primate models for related vaccine development. In order to apply vaccine approaches in the HIV-2 and SIV models to the HIV-1 system, subunit vaccines for these viruses would be useful.
One of the principal features of an effective AIDS vaccine will be the ability to elicit neutralizing antibody. The principal neutralizing determinant of HIV-1 has been localized between two cysteine residues in the third variable domain, the V3 loop, of the external envelope glycoprotein, gpl20 (11, 20, 23, 31) . While the HIV-1 V3 loop elicits highly type-specific neutralizing antibody, humans naturally infected with the virus develop antibodies capable of neutral-* Corresponding author.
izing a broad spectrum of HIV isolates (38) . This property may be due, at least in part, to reactivities directed against the conserved tip of the V3 loop (15) . The ability to elicit such a broad immune response has obvious advantages for vaccine development.
Previous reports have demonstrated cross-neutralization of HIV-1 and -2 by antibody-positive human sera (2, 3, 39) . We show here that cross-neutralization by sera of humans and monkeys infected with HIV-2, SIVMAC, and SIVAGM isolates is more extensive than the infrequent and low-titer cross-neutralizations observed between HIV-1 and -2. Cross-neutralization must reflect conservation of neutralizing epitope. As significant homology exists between the V3 loops of HIV-2 and SIV isolates, we examined the role of the V3 loop of these viruses in neutralization and the immunologic cross-reactivities among them. We show that HIV-2, SIVMAC, and SIVAGM isolates are more similar to each other than to HIV-1 in cross-neutralization properties and in reactivity to complete or partial linear V3 loop peptides. The activity patterns observed reflect the evolutionary relatedness of the envelope genes of these virus isolates (10) . In this regard, while the use of linear peptides to elicit neutralizing antibody may be very effective in the HIV-1 system, subunit vaccine approaches in the HIV-2 and SIV macaque models, while similar in theory, may need to differ significantly in character.
MATERIALS AND METHODS
Sera. Human sera possessing antibodies to HIV-1 or -2 represented individuals both asymptomatic and with AIDS. Viruses. Established isolates of HIV-1 (HTLV-IIIB [24] , HTLV-IIIRF [24] , and RUTZ [38] ) and of HIV-2 (NIH-Z [41] ) and the infectious molecularly cloned virus, SBL/ISY (5) Assay for neutralizing antibody. Neutralizing antibody activity was determined as previously described (28, 29 (Table 2) .
In contrast to the weak cross-neutralizations observed between HIV-1 and the other immunodeficiency viruses studied, the cross-neutralization results of HIV-2 and SIV isolates were striking. The majority of serum samples of HIV-2-infected humans, of macaques or a baboon experimentally infected with SIVMAC, and of African green monkeys naturally infected with SIVAGM were able to crossneutralize the HIV-2 and SIV isolates studied, with both a high titer and a high frequency ( Table 2) . Analysis of the cross-neutralization patterns suggests that HIV-2 is immunologically more closely related to SIVMAC than to SIVAGM, while SIVAGM is more closely related to SIVMAC than to HIV-2. HIV-2 and SIVMAC isolates were cross-neutralized by 88 to 100% of HIV-2-and SIVMAC-positive sera, with titers ranging from 275 to 590, and SIVMAC and SIVAGM isolates were cross-neutralized by 75 to 100% of SIVMACand SIVAGM-positive sera, with titers ranging from 145 to 300. The HIV-2-and SIVAGM-positive sera cross-neutralized their respective isolates with lower frequency (14 to 60%) and with only a modest titer (70 to 75). The immunological relationships of these viruses parallel their genetic relatedness. With regard to the envelope gene, SIVAGM is slightly more related to SIVMAC than to HIV-2.
Analysis of V3 loop regions. Cross-neutralization reflects conservation of neutralizing epitopes among isolates. The less than 30% homology (Fig. 1) of the V3 loop regions of HIV-1 and HIV-2, represented by the MN, NIH-Z, and SBL/ISY isolates, suggests that an alternate epitope(s) may be responsible for the cross-neutralization observed between these two viral types. The V3 region of HIV-2 has been predicted to form a loop, similar to that of HIV-1 (17) . In addition, significant conservation of the V3 region sequence of HIV-2 and SIV isolates occurs at both the amino and carboxy termini of the loops as well as in the central portion (Fig. 1) , similar to the homology observed among HIV-1 V3 loops (16) . This sequence conservation together with the overall envelope structure of the HIV-2 and SIVs suggests that this V3 region might constitute a neutralizing epitope and also contribute to the cross-neutralization observed. Therefore, we initially examined cross-reactivity patterns of HIV-2-and SIV-positive sera to various V3 loop peptides. Figure 2 illustrates the results of peptide-binding ELISAs of human and nonhuman primate neutralizing sera. The SIVMAC-and SIVAGM-positive sera tested possessed excellent binding reactivities for the homologous and heterologous SIV V3 loop peptides. All were capable of reacting with both of these V3 loops. In addition, the majority of these Binding is expressed as the ratio of the absorbance of test serum to the absorbance of a standard negative control serum. The dashed lines represent the ratio of 3, below which samples were considered negative. The V3 loops tested, as noted at the top, are those within the boxed area of Fig. 1 6 ).
In the HIV-1 system, the conserved crown of the V3 loop, the GPGR sequence, plays a major role in immunologic cross-reactivity and neutralization (15) . We investigated whether the observed cross-reactivity between HIV-2, SIVMAC251, and SIVAGM2(K could be attributed to the conserved crown region of these viruses.
This putative crown consists of the conserved amino acids FHSQ and either K in HIV-2sBL/Isy and SIVAGM or P in HIV-2N1Hz and SIVMAC (Fig. 1) . Comparison of Fig. 2 and   3 shows that while both the SIVAGM-and SIVMAC-positive sera reacted strongly with their homologous V3 loop peptide, as well as with the corresponding heterologous peptide, the SIVAGM-positive sera were much better able to bind their homologous crown peptide. The alteration of a single amino acid in this crown peptide resulted in significantly less binding to the heterologous peptide. In comparison, the SIVMAC-positive sera exhibited good binding to both homologous and heterologous crown peptides. The HIV-2-positive sera, however, were completely unable to recognize either crown peptide. Thus, the conserved central region of the V3 loops of HIV-2 and SIV isolates does not seem responsible for the observed cross-reactive binding activities. 
DISCUSSION
The ability of HIV-2 and SIV isolates to be cross-neutralized by their respective antisera, together with their poor or nonexistent cross-neutralization of the HIV-1 isolates, was striking. However, a recent analysis of evolutionary relationships suggests that with regard to the env gene, SIVAGM, as well as SIVMND, is more related to the HIV-2 group of viruses, together with SIVMAC and SIVSM, than to the HIV-1 group (10). This relationship is reflected by the extensive homology among the V3 loops of the isolates studied (Fig. 1) Fig. 1 and 2 ). However, very poor binding to the NIH-Z V3 loop peptide, which shares considerable homology with the other V3 loops (Fig. 1) , was observed. Conformational differences in this peptide may explain the data. The SIVMAC-positive sera exhibited the greatest crossreactivity, presumably directed in part to the crown region. They possessed reactivity to both linear crown peptides (Fig. 3) in contrast to the African green monkey sera with which a single amino acid substitution abolished binding activity in all but one of the serum samples (Fig. 3) . The (25) . While the primate sera studied were able to bind at least their homologous crown peptide (Fig. 3) , the HIV-2-positive sera could not recognize these linear peptides at all. Moreover, the crown peptides were not able to absorb neutralizing activity from either the HIV-2-or SIVMAC-positive sera (data not shown). Thus, these studies suggest that in contrast to the HIV-1 system, this central V3 region, although highly conserved, is not responsible for neutralization of HIV-2 or SIV in a linear format.
Although the number of serum samples studied was small, the level of cross-neutralization observed between HIV-2 and SIV isolates suggests a structural and functional similarity of these viruses and sets them apart from HIV-1. (30) was shown to result in neutralization resistance (27) , apparently due to conformational changes (40) . Broadly reactive, conformation-dependent neutralizing antibodies which do not recognize the V3 loop have been purified from HIV-1-positive human sera by affinity chromatography on native, glycosylated, denatured envelope protein (36) . In addition, characterization of a broadly reactive human neutralizing monoclonal antibody has suggested that it recognizes four noncontiguous sites on the viral envelope (37) 
